Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-7249 Phase 1 in Healthy Subjects
NCT06541457Phase 1Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Aug 2024
- Primary completion
- Jul 2025
- Modality
- Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HRS-7249 in hyperlipidemia (6 arms), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoint: Incidence of subjects with adverse events (AEs) at Day 169. Started Aug 2024; status: completed.
02
Drugs
HRS-7249
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT06541457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06541457.